Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.

MLA

Harrison, Stephen A., et al. “Aldafermin in Patients with Non-Alcoholic Steatohepatitis (ALPINE 2/3): A Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial.” The Lancet. Gastroenterology & Hepatology, vol. 7, no. 7, July 2022, pp. 603–16. EBSCOhost, https://doi.org/10.1016/S2468-1253(22)00017-6.

APA

Harrison, S. A., Abdelmalek, M. F., Neff, G., Gunn, N., Guy, C. D., Alkhouri, N., Bashir, M. R., Freilich, B., Kohli, A., Khazanchi, A., Sheikh, M. Y., Leibowitz, M., Rinella, M. E., Siddiqui, M. S., Kipnes, M., Moussa, S. E., Younes, Z. H., Bansal, M., Baum, S. J., … Lieu, H. D. (2022). Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. The Lancet. Gastroenterology & Hepatology, 7(7), 603–616. https://doi.org/10.1016/S2468-1253(22)00017-6

Chicago

Harrison, Stephen A, Manal F Abdelmalek, Guy Neff, Nadege Gunn, Cynthia D Guy, Naim Alkhouri, Mustafa R Bashir, et al. 2022. “Aldafermin in Patients with Non-Alcoholic Steatohepatitis (ALPINE 2/3): A Randomised, Double-Blind, Placebo-Controlled, Phase 2b Trial.” The Lancet. Gastroenterology & Hepatology 7 (7): 603–16. doi:10.1016/S2468-1253(22)00017-6.